Angiopoietin-1 Gene Therapy Attenuates Hypertension and Target Organ Damage in Nitric Oxide Synthase Inhibited Spontaneously Hypertensive Rats

Background and Objectives In our previous study, we found that the gene transfer of a potent derivative of cartilage oligomeric matrix protein Angiopoietin-1 (COMP-Ang-1) substantially prevented hypertension, microvascular rarefaction, and target organ damage in spontaneously hypertensive rats (SHRs). The purpose of the present study was to examine the role of nitric oxide (NO) in the therapeutic effects observed after COMP-Ang-1 gene transfer. Materials and Methods To exclude the NO-mediated effects in COMP-Ang-1 gene therapy, the SHRs were treated with an NO synthase (NOS) inhibitor, Nw-nitro-L-arginine methyl ester (L-NAME) before the electrophoretic gene transfer. Results The pretreatment with L-NAME induced a severe and sustained increase in systolic blood pressure (BP) in a LacZ plasmid transferred control SHR. However, the electrophoretic transfer of a COMP-Ang-1 plasmid instead of LacZ plasmid in L-NAME-pretreated SHRs substantially blocked the development of hypertension without any significant difference in comparison with L-NAME-untreated COMP-Ang-1 plasmid transferred groups. In addition, the COMP-Ang-1 plasmid transfer substantially attenuated microvascular rarefaction and arteriole remodeling in the heart and kidney, which might account for the mild histological alterations observed in the COMP-Ang-1 plasmid transferred group, in contrast to the severe fibrosis and necrosis seen in the LacZ plasmid controls. Conclusion These therapeutic outcomes of COMP-Ang-1 gene transfer even in NOS inhibited SHRs suggested that the antihypertensive effect of COMP-Ang-1 was not merely secondary to NO-mediated vasorelaxation, but it may be associated with its ability to protect the vascular endothelium probably via an NO-independent mechanism which serves to attenuate microvascular rarefaction and target organ damage, and also to prevent hypertension by reducing peripheral vascular resistance.

[1]  J. Park,et al.  The Effect of Telmisartan on Endothelial Function and Arterial Stiffness in Patients With Essential Hypertension , 2009, Korean circulation journal.

[2]  Y. Suh,et al.  Angiopoietin-1 prevents hypertension and target organ damage through its interaction with endothelial Tie2 receptor , 2008, Cardiovascular research.

[3]  E. Battegay,et al.  Effects of anti-hypertensive drugs on vessel rarefaction. , 2007, Current opinion in pharmacology.

[4]  K. Jang,et al.  COMP-angiopoietin-1 ameliorates renal fibrosis in a unilateral ureteral obstruction model. , 2006, Journal of the American Society of Nephrology : JASN.

[5]  M. Laville,et al.  Is hypertension a tissue perfusion disorder? Implications for renal and myocardial perfusion , 2006, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[6]  G. Cohuet,et al.  Mechanisms of target organ damage caused by hypertension: therapeutic potential. , 2006, Pharmacology & therapeutics.

[7]  Chung-Hyun Cho,et al.  COMP-angiopoietin-1 promotes wound healing through enhanced angiogenesis, lymphangiogenesis, and blood flow in a diabetic mouse model. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[8]  J. Redón.  Antihypertensive treatment: should it be titrated to blood pressure reduction or to target organ damage regression? , 2005, Current opinion in nephrology and hypertension.

[9]  H. Kobori,et al.  Enhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive rats. , 2005, Journal of the American Society of Nephrology : JASN.

[10]  D. Behm,et al.  Hypertensive target organ damage is attenuated by a p38 MAPK inhibitor: role of systemic blood pressure and endothelial protection. , 2005, Cardiovascular research.

[11]  R. Kammerer,et al.  Designed angiopoietin-1 variant, COMP-Ang1, protects against radiation-induced endothelial cell apoptosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[12]  N. Markandu,et al.  Rarefaction of skin capillaries in normotensive offspring of individuals with essential hypertension , 2003, Heart.

[13]  D. Su,et al.  Effects of Long-term Treatment with Ketanserin on Blood Pressure Variability and End-Organ Damage in Spontaneously Hypertensive Rats , 2003, Journal of cardiovascular pharmacology.

[14]  B. Lévy,et al.  Role of microvascular rarefaction in the increased arterial pressure in mice lacking for the endothelial nitric oxide synthase gene (eNOS3pt−/−) , 2002, Journal of hypertension.

[15]  B. Lévy,et al.  Decreased arteriolar density in endothelial nitric oxide synthase knockout mice is due to hypertension, not to the constitutive defect in endothelial nitric oxide synthase enzyme , 2002, Journal of hypertension.

[16]  A. Pries,et al.  Microcirculation in Hypertension: A New Target for Treatment? , 2001, Circulation.

[17]  E. Frohlich,et al.  Angiotensin Type 1 Receptor Antagonism and ACE Inhibition Produce Similar Renoprotection in N&ohgr;-Nitro-l-Arginine Methyl Ester/Spontaneously Hypertensive Rats , 2001, Hypertension.

[18]  N. Markandu,et al.  Rarefaction of skin capillaries in borderline essential hypertension suggests an early structural abnormality. , 1999, Hypertension.

[19]  A C Shore,et al.  Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. , 1997, The Journal of clinical investigation.